Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT03227276
Other study ID # INQ/004317
Secondary ID
Status Completed
Phase N/A
First received
Last updated
Start date August 14, 2017
Est. completion date February 19, 2020

Study information

Verified date February 2020
Source InQpharm Group
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

To evaluate the efficacy of Litramine in reducing body weight in the context of an energy-restricted diet in overweight and moderately obese subjects


Recruitment information / eligibility

Status Completed
Enrollment 166
Est. completion date February 19, 2020
Est. primary completion date February 19, 2020
Accepts healthy volunteers Accepts Healthy Volunteers
Gender All
Age group 18 Years to 70 Years
Eligibility Inclusion Criteria:

1. Men and women from 18 to 70 years old

2. Overweight (BMI 25 kg/m2 - 29.9 kg/m2) for 80% of randomized subjects and obese (BMI 30 kg/m2 - 34.9 kg/m2) for 20% of randomized subjects

3. Generally in good health

4. Desire to lose weight

5. Readiness and ability to complete the 1-year study, according to investigator's judgement following the screening interview

6. Accustomed to regular daily consumption of 3 main meals (breakfast, lunch, dinner)

7. Consistent and stable body weight in the last 3 months prior to V1 (less than 5% self- reported change)

8. Subject's agreement to comply with study procedures, in particular:

- to take IP as recommended

- to avoid the use of other weight loss and/or management products and/or programs during the study

- to adhere to diet recommendation during the study

- to complete the subject diary and study questionnaires

9. Women of childbearing potential:

- commitment to use contraception methods

- negative pregnancy testing (beta human chorionic gonadotropin test in urine) at V1

10. Written informed consent

Exclusion Criteria:

1. Known allergy or hypersensitivity to the components of the investigational products or source plants

2. Pathological electrocardiogram (ECG) at V1

3. History and/or presence of clinically significant condition/disorder, which per investigator's judgement could interfere with the results of the study or the safety of the subject, e.g.:

- untreated or unstable thyroid gland disorder

- untreated or unstable hypertension (regular blood pressure >140/90 mm Hg)

- acute or chronic gastrointestinal (GI) disease or digestion/absorption disorders (e.g.

inflammatory bowel disease, coeliac disease, pancreatitis etc.)

- diabetes mellitus type 1

- untreated or unstable diabetes mellitus type 2

- any other serious organ or systemic diseases that could influence the conduct and/or outcome of the study and/or could affect the tolerability of the subject

4. Significant surgery within the last 6 months prior to V1:

- GI surgery

- liposuction

5. History of eating disorders like bulimia, anorexia nervosa, binge-eating within the last 12 months prior to V1

6. Deviation of safety laboratory parameter(s) at V1 that is:

- clinically significant or

- >2x upper limit of normal, unless the deviation is justified by a previously known not clinically relevant condition (e.g. Gilbert's syndrome)

7. Any electronic medical implant

8. Regular medication and/or supplementation and/or treatment within the last 3 months prior to V1 and during the study:

- that could influence body weight (e.g. systemic corticosteroids)

- that could influence gastrointestinal functions (e.g. laxatives, opioids, anticholinergics etc.) as per investigator judgement

- for weight management (e.g. fat binder, carbohydrate/starch blocker, fat burner, satiety products, acupuncture etc.)

9. Smoking cessation within 6 months prior to V1 or during the study (regular smoking during the study at the same level as prior to the study is allowed)

10. Women of child-bearing potential: pregnancy or nursing

11. History of or current abuse of drugs, alcohol or medication

12. Participation in another clinical study in the 30 days prior to V1 and during the study

13. Any other reason for exclusion as per investigator's judgment, e.g. insufficient compliance with study procedures

Study Design


Intervention

Dietary Supplement:
Litramine
2 tablets to be taken 3 times a day after meals
Placebo tablet
2 tablets to be taken 3 times a day after meals

Locations

Country Name City State
Germany Analyze & Realize Berlin

Sponsors (1)

Lead Sponsor Collaborator
InQpharm Group

Country where clinical trial is conducted

Germany, 

Outcome

Type Measure Description Time frame Safety issue
Other Adverse effects Assessment of adverse events throughout the study 52 weeks
Other Safety parameters (Lab parameters, vital signs) Assessment of laboratory results in full blood count, clinical chemistry, blood pressure and pulse rate 52 weeks
Primary Difference in mean body weight (kg) of overweight subjects Difference in mean body weight (kg) of overweight subjects after 52 weeks of IP intake in comparison between verum and placebo 52 weeks
Secondary Difference in mean body weight (kg) of all subjects 52 weeks
Secondary Difference in mean body weight (kg) of obese subjects 52 weeks
Secondary Proportion of subjects who lost at least 3%, 5% and 10% of baseline body weight 52 weeks
See also
  Status Clinical Trial Phase
Not yet recruiting NCT03994419 - PErioperAtive CHildhood ObesitY
Recruiting NCT05354245 - Using a Complex Carbohydrate Mixture to Steer Fermentation and Improve Metabolism in Adults With Overweight and Prediabetes (DISTAL) N/A
Completed NCT03602001 - Attentive Eating for Weight Loss N/A
Recruiting NCT06269159 - The Power of 24-hour: Co-designing Intervention Components
Completed NCT03377244 - Healthy Body Healthy Souls in the Marshallese Population N/A
Completed NCT02996864 - Location-based Smartphone Technology to Guide College Students Healthy Choices Ph II N/A
Terminated NCT03914066 - A Group-based Treatment of Overweight and Obesity in Primary Care N/A
Completed NCT04647149 - Effects of Early and Delayed Time-restricted Eating in Adults With Overweight and Obesity N/A
Completed NCT03685656 - Effect of ANACA3 Slimming Gel on Loss of Abdominal and Thigh Circumferences in Healthy Volunteers N/A
Completed NCT05051579 - A Study of LY3502970 in Participants With Obesity or Overweight With Weight-related Comorbidities Phase 2
Completed NCT04611477 - Effect of Synbiotic 365 on Body Composition in Overweight and Obese Individuals N/A
Active, not recruiting NCT05330247 - Cut Down on Carbohydrate in the Dietary Therapy of Type 2 Diabetes - The Meal Box Study N/A
Completed NCT03599115 - Effects of Inhibitory Control Training in Eating Behaviors N/A
Recruiting NCT05938894 - Train Your Brain - Executive Function N/A
Recruiting NCT06094231 - Treating Patients With Renal Impairment and Altered Glucose MetAbolism With TherapeutIc Carbohydrate Restriction and Sglt2-Inhibiton - a Pilot Study N/A
Recruiting NCT05987306 - A Self-compassion Focused Intervention for Internalized Weight Bias and Weight Loss N/A
Completed NCT03792685 - Looking for Personalized Nutrition for Obesity/Type 2 Diabetes Mellitus Prevention N/A
Completed NCT05055362 - Effect a Honey, Spice-blended Baked Good Has on Salivary Inflammation Markers in Adults: a Pilot Study N/A
Completed NCT04520256 - Rapid Evaluation of Innovative Intervention Components to Maximize the Health Benefits of Behavioral Obesity Treatment Delivered Online: An Application of Multiphase Optimization Strategy Phase 2/Phase 3
Completed NCT04979234 - A Single Centre, Prospective Feasibility Study to Evaluate the Efficacy of an Endoluminal-suturing Device (Endomina) on Severe Obstructive Sleep Apnea Syndrome N/A